Education
About Us
Working with TipRanks
Follow Us
Hookipa Pharma Inc (HOOK)
NASDAQ:HOOK
HOOK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.41 - $10.50
Previous CloseN/A
Volume38.61K
Average Volume (3M)55.97K
Market Cap
$18.44M
Enterprise Value-$3.01M
Total Cash (Recent Filing)$127.72M
Total Debt (Recent Filing)$9.89M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 20, 2025EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding9,659,522
10 Day Avg. Volume71,764
30 Day Avg. Volume55,972
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.37
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$2.00Price Target Upside43.88% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Hookipa Pharma News
PremiumCompany Announcements
Hookipa Pharma Seeks Validation for Stockholder Meetings
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe ongoing Phase 1/2 has completed enrollment well in advance of plan, and updated results continued to highlight the potential superior results for eseba-vec + Keytruda vs. Keytruda monotherapy.
Partnerships And CollaborationsHOOKIPA will continue to enroll the Phase 1b for its HIV therapeutic vaccine under its partnership with Gilead.
Bears Say
Financial PerformanceHookipa had approximately $60M in cash, which is believed to be insufficient to support the company to realize meaningful value inflection points from its own pipeline.
---
Ownership Overview
3.50% Insiders
5.29% Mutual Funds
39.52% Other Institutional Investors
49.16% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOOK FAQ
What was Hookipa Pharma Inc’s price range in the past 12 months?
Hookipa Pharma Inc lowest stock price was $1.41 and its highest was $10.50 in the past 12 months.
What is Hookipa Pharma Inc’s market cap?
Hookipa Pharma Inc’s market cap is $18.44M.
When is Hookipa Pharma Inc’s upcoming earnings report date?
Hookipa Pharma Inc’s upcoming earnings report date is Mar 20, 2025 which is in 15 days.
How were Hookipa Pharma Inc’s earnings last quarter?
Hookipa Pharma Inc released its earnings results on Nov 14, 2024. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.28 by $0.18.
Is Hookipa Pharma Inc overvalued?
According to Wall Street analysts Hookipa Pharma Inc’s price is currently Undervalued.
Does Hookipa Pharma Inc pay dividends?
Hookipa Pharma Inc does not currently pay dividends.
What is Hookipa Pharma Inc’s EPS estimate?
Hookipa Pharma Inc’s EPS estimate is -1.12.
How many shares outstanding does Hookipa Pharma Inc have?
Hookipa Pharma Inc has 9,659,522 shares outstanding.
What happened to Hookipa Pharma Inc’s price movement after its last earnings report?
Hookipa Pharma Inc reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.28. Following the earnings report the stock price went down -4.459%.
Which hedge fund is a major shareholder of Hookipa Pharma Inc?
Currently, no hedge funds are holding shares in HOOK
---
Company Description
Hookipa Pharma Inc
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
---
HOOK Stock 12 Month Forecast
Average Price Target
$2.00
▲(43.88% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
BeiGene
―
Best Analysts Covering HOOK
1 Year
1 Year Success Rate
1/22 ratings generated profit
1 Year Average Return
-58.41%
reiterated a buy rating 7 months ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 4.55% of your transactions generating a profit, with an average return of -58.41% per trade.
---